Lupi-HMG 150 Injection contains Menotrophin (150 IU), a purified preparation of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) derived from the urine of postmenopausal women. It is indicated for use in assisted reproductive technologies and ovulation induction in women with anovulatory infertility due to hypogonadotropic hypogonadism or other causes where endogenous gonadotropin secretion is insufficient. Menotrophin acts by stimulating the development of ovarian follicles, promoting follicular maturation, and supporting ovulation. Additionally, it is utilized in male patients to stimulate spermatogenesis in cases of hypogonadotropic hypogonadism. Lupi-HMG 150 Injection is administered via intramuscular or subcutaneous injection, with dosing individualized based on patient response and monitored through hormonal assays and ultrasound evaluation of follicular development. Treatment should be conducted under strict medical supervision to minimize risks such as ovarian hyperstimulation syndrome (OHSS) and multiple pregnancies. Contraindications include primary ovarian failure, uncontrolled thyroid or adrenal dysfunction, pregnancy, and hypersensitivity to menotrophins. Adverse effects may include local injection site reactions, headache, abdominal discomfort, and rarely, allergic reactions. Proper patient selection, monitoring, and adherence to recommended dosing protocols are essential to optimize therapeutic outcomes and ensure patient safety.